Investors in Nigeria’s pharmaceutical sector are closely watching the performance of Fidson Healthcare Plc and May & Baker Nigeria Plc, as both companies position themselves to capture a larger share of the country’s growing drug and healthcare market.
With increased demand for locally manufactured medicines following supply chain disruptions, currency volatility, and government emphasis on self-reliance, both firms have shown resilience. However, analysts say the question for investors is which of the two represents the better buy at the moment.
Fidson Healthcare Plc
Fidson has established itself as one of Nigeria’s leading pharmaceutical manufacturers, with a wide product portfolio that includes antibiotics, antimalarials, multivitamins, and over-the-counter medications. The company has continued to expand its production capacity, supported by investments in a World Health Organization (WHO)-certified facility.
Its revenue growth has been driven by strong domestic demand, though margins remain pressured by rising input costs and foreign exchange challenges. Analysts note that Fidson’s emphasis on innovation and brand loyalty provides a competitive edge, while its dividend history remains attractive to income-focused investors.
May & Baker Nigeria Plc
Founded in 1944, May & Baker is one of Nigeria’s oldest pharmaceutical companies, with a legacy in prescription drugs, vaccines, and consumer healthcare products. The company has benefited from strategic collaborations, including past partnerships with global institutions in vaccine production.
Recent financial results have shown improvements in profitability, partly due to operational efficiencies and cost-cutting measures. May & Baker’s long-standing reputation and distribution network are seen as strengths, though concerns persist over its relatively slower pace of product diversification compared to newer rivals.
Analysts’ Verdict
Market watchers say Fidson currently holds an edge in terms of growth potential, given its aggressive expansion and stronger product pipeline. However, May & Baker remains a solid long-term player, appealing to investors seeking stability and consistent returns.
Both stocks are considered undervalued in comparison to global pharmaceutical peers, making the sector attractive for medium- to long-term investors. Ultimately, analysts recommend that investors weigh their risk appetite: Fidson for growth and expansion, May & Baker for stability and heritage.
